Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03317925 · ClinicalTrials.gov registry record
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)
A clinical trial of Renal Transplant and Rejection Chronic Renal, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 29
- Enrollment target
- 1
- Study location
NCT03317925 is a study of Renal Transplant and Rejection Chronic Renal that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 29 participants, below the 46-participant average among 5 other Renal Transplant trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03317925, a study of Renal Transplant and Rejection Chronic Renal, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
In pediatric kidney transplant patients, rejection, medication toxicity and ischemia cause early and chronic renal allograft injury, which reduces graft lifespan and patient survival. Early detection of injury would facilitate prevention and treatment. The gold standard surveillance biopsy has limitations including delayed discovery of injury. No noninvasive test identifies graft injury before it is clinically apparent. This project's goal is to develop a novel early marker of subclinical graft injury to facilitate prompt recognition and treatment.
Conditions Studied
Interventions
- PROCEDURE Renal Transplantation
Study Locations (1)
North Carolina
- Wake Forest University Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-07-16 |
| Est. Completion | 2017-04-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03317925
The ClinicalTrials.gov registry entry for NCT03317925 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 5 other Renal Transplant trials with a reported enrollment target (37% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Renal Transplant appearing as the primary indexed condition, and to 1 intervention - of which Renal Transplantation is the first listed.
NCT03317925 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03317925 about?
NCT03317925 is a clinical study titled "Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)". In pediatric kidney transplant patients, rejection, medication toxicity and ischemia cause early and chronic renal allograft injury, which reduces graft lifespan and patient survival. Early detection of injury would facilitate prevention and treatment. The gold standard surveillance biopsy has limit...
What is the current status of trial NCT03317925?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2014-07-16. Estimated completion is 2017-04-26.
What conditions does trial NCT03317925 study?
This clinical trial studies the following conditions: Renal Transplant, Rejection Chronic Renal, Renin-Angiotensin System, Rejection Acute Renal, Rejection of Renal Transplant.
What interventions are being tested in trial NCT03317925?
The interventions under investigation include: Renal Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03317925?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03317925 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™
ACTIVE NOT RECRUITING · Phase 4
-
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
COMPLETED · Phase 4
-
"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"
COMPLETED · Phase 2
-
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.